Claims for Patent: 8,211,429

Summary for Patent: 8,211,429

Title:	Neuropilin antagonists
Abstract:	Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.
Inventor(s):	Watts; Ryan J. (San Mateo, CA), Wu; Yan (Foster City, CA)
Assignee:	Genetech, Inc. (South San Francisco, CA)
Application Number:	13/173,890
Patent Claims:	1. A method for treating a mammal suffering from a disorder associated with pathological angiogenesis comprising administering an anti-neuropilin-1 (NRP1) antibody capable of inhibiting at least one neuropilin (NRP) mediated biological activity, which comprises a light chain variable domain comprising the following CDR amino acid sequences: CDRL1 (RASQYFSSYLA; SEQ ID NO: 129), CDRL2 (GASSRAS; SEQ ID NO: 130) and CDRL3 (QQYLGSPPT; SEQ ID NO: 131) for the treatment of a disorder associated with pathological angiogenesis in a mammal. 2. The method of claim 1, wherein the antibody comprises a light chain variable domain sequence of SEQ ID NO: 5. 3. The method of claim 1, wherein the antibody comprises a heavy chain variable domain comprising the following CDR amino acid sequences: CDRH1(GFTFSSYAMS; SEQ ID NO: 132), CDRH2 (SQISPAGGYTNYADSVKG; SEQ ID NO: 133) and CDRH3 (ELPYYRMSKVMDV; SEQ ID NO: 134). 4. The method of claim 3, wherein the antibody comprises a heavy chain variable domain sequence of SEQ ID NO: 6 or SEQ ID NO: 135. 5. The method of claim 1, wherein the antibody comprises a light chain variable domain sequence of SEQ ID NO:5 and a heavy chain variable domain sequence of SEQ ID NO: 6 or SEQ ID NO: 135. 6. The method of claim 1, wherein the antibody is a bispecific antibody. 7. The method of claim 6, wherein the bispecific antibody also binds to hVEGF. 8. The method of claim 7, wherein the portion of the antibody that binds to hVEGF is capable of binding to the same VEGF epitope as the antibody A4.6.1. 9. The method of claim 1, wherein the disorder is a cancer. 10. The method of claim 9, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer, renal cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, and mesothelioma. 11. The method of claim 10, wherein the treatment further comprises a second therapeutic agent. 12. The method of claim 11, wherein the second therapeutic agent is an agent selected from the group consisting of an anti-angiogenic agent, an anti -neoplastic composition, a chemotherapeutic agent and a cytotoxic agent. 13. The method of claim 12, wherein the anti-angiogenic agent is a VEGF antagonist. 14. The method of claim 13, wherein the VEGF antagonist is an anti-hVEGF antibody. 15. The method of claim 14, wherein the anti-hVEGF antibody is capable of binding to the same VEGF epitope as the antibody A4.6.1. 16. The method of claim 15, wherein the anti-hVEGF antibody is bevacizumab or ranibizumab. 17. The method of claim 12, wherein the second therapeutic agent is a receptor tyrosine kinase inhibitor selected from the group consisting of vatalanib (PTK787), erlotinib (TARCEVA.RTM.), OSI-7904, ZD6474 (ZACTIMA.RTM.), ZD6126 (ANG453), ZD1839, sunitinib (SUTENT.RTM.), semaxanib (SU5416), AMG706, AG013736, Imatinib (GLEEVEC.RTM.), MLN-518, CEP-701, PKC-412, Lapatinib (GW572016), bortezomib (VELCADE.RTM.), AZD2171, sorafenib (NEXAVAR.RTM.), XL880, and CHIR-265. 18. The method of claim 1, wherein the mammal is a human.

Details for Patent 8,211,429

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2025-11-08
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2025-11-08
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2025-11-08
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2025-11-08
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2025-11-08